A novel frameshift RPL15 gene variant associated with hydrops fetalis and perinatal death Xiaoling Chen, Ke Wu, Bo Zhu Abstract BackgroundThe heterozygous RPL15 gene (OMIM*604174) variants are associated with autosomal dominant Diamond-Blackfan anemia 12 (DBA12, OMIM#615550). Fewer than ten RPL15 variants have been reported to date, and they are commonly associated with hydrops fetalis, intrauterine growth restriction (IUGR) and neonatal anemia. Fetal demise attributable to the RPL15 variant identified in our patient was the first documented case of perinatal death associated with RPL15-related DBA.MethodsTrio-based whole-exome sequencing (trio-WES) was performed on genomic DNA (gDNA) of fetal muscular tissues and parental peripheral blood samples. Mutant RPL15 expression vectors pcDNA3.1 (+)-FLAG-RPL15-mut and control pcDNA3.1 (+)-FLAG-RPL15-wt mammalian expression vectors were constructed. Both vectors were subsequently transformed into HEK293 T cells. Assays measuring the relative expression of RPL15 gene mRNA and RPL15 protein were performed. Actinomycin D was used to detect the degradation of RPL15 mRNA. Meanwhile, we reviewed previously reported RPL15-related cases with available clinical data, including relevant genetic testing results and prenatal/postnatal manifestations.ResultsTrio-WES identified a novel heterozygous frameshift RPL15 gene variant (NM_002948.5) c.227del (p.Pro76Leufs*17) in this fetus. The relative expression of RPL15 gene mRNA analysis showed that the mRNA expression of mutant RPL15 cell lines was significantly decreased, and the relative expression level of RPL15 protein in the RPL15-mut cell lines was significantly lower than that in the RPL15-wt cell lines (P < 0.0001). After actinomycin D treatment, mRNA transcription was inhibited in both the RPL15-wt and RPL15-mut cell lines; the RPL15-mut cell lines exhibited a significantly accelerated mRNA decay rate and lower mRNA expression relative to the RPL15-wt cell lines. All these results revealed that this variant resulted in a dramatic reduction in the formation of RPL15 protein due to the decay of mutant RPL15 mRNA. After reviewing the current literature, we found that fetuses with RPL15 gene variants commonly presented with hydrops fetalis, intrauterine growth restriction, and heart defect. The penetrance of loss-of-function variants in the RPL15 gene was high, but appears to be incomplete.ConclusionFetuses with RPL15 gene variants can present with hydrops fetalis, IUGR, heart defects, decreased fetal movements, and extremity abnormalities. Our functional studies have provided preliminary evidence confirming the haploinsufficiency of the RPL15 gene as the underlying pathogenic mechanism of DBA12. This study also expands the mutational spectrum of the RPL15 gene and broadens the associated clinical spectrum of DBA12. Introduction Hydrops fetalis (HF) is characterized by abnormal interstitial fluid accumulation within at least two fetal body compartments detected by ultrasound, including pericardial effusion, pleural effusion, ascites and skin oedema (). The pathophysiology of HF can be classified according to immune and nonimmune etiology. Nonimmune hydrops fetalis (NIHF) accounts for almost 90% of hydrops cases (). NIHF is associated with a high perinatal mortality rate ranging from 50% to 98% (). A systematic review and meta-analysis revealed that the diagnostic yield of prenatal exome sequencing for NIHF was about 37% (). Herein, we present an extremely rare case of hydrops fetalis caused by a novel frameshift variant in the RPL15 gene, resulting in perinatal lethality. The heterozygous RPL15 gene (OMIM*604174) variants are associated with autosomal dominant Diamond-Blackfan anemia 12 (DBA12, OMIM#615550). The hallmark of DBA is haploinsufficiency of ribosomal protein gene, which disrupts ribosomal RNA (rRNA) maturation and stability of the ribosome. Impaired ribosome biogenesis triggers nucleolar stress, leading to TP53 stabilization and activation, which in turn induces apoptosis and disrupts differentiation of erythroid progenitor cells (). Fetuses harboring RPL15 gene variants commonly present with hydrops fetalis and IUGR. After reviewing the current literature, we found that fetal demise attributable to the RPL15 variant identified in our patient was the first documented case of perinatal death associated with RPL15-related DBA. We also performed a series of functional studies on this variant, which preliminarily suggested that the pathogenic mechanism of DBA12 may be associated with RPL15 haploinsufficiency. Materials and methods Whole-exome sequencing (WES) Trio-based whole-exome sequencing (trio-WES) was performed on genomic DNA (gDNA) of fetal muscular tissues and parental peripheral blood samples using Genome Column Medium Extraction Kit (Kangweishiji, China) according to the manufacturer’s instructions. The extracted DNA samples were subjected to quality control using a Qubit 2.0 fluorimeter and electrophoresis with a 0.8% agarose gel for further protocols. The xGenTM Exome Research Panel v2 (designed by Integrated DNA Technologies) was used for WES. Quality control (QC) of the DNA library was performed using an Agilent 2,100 Bioanalyzer System (Agilent, United States of America). DNA nanoball (DNB) preps of clinical samples were sequenced on ultra high throughput DNBSEQ-T7 platform (MGI, Shenzhen, China) with paired-end 150 nt strategy following manufacturer’s protocol. For more details, please refer to the (the process of whole-exome sequencing analysis) and 2 (a comprehensive list of candidate variants). Bioinformatic analysis Sequencing data were analyzed according to our in-house (Chigene Translational Medicine Research Center) procedures. Raw data were processed to remove adapters and filter out low-quality reads. The trimmed reads were then mapped to the University of California at Santa Cruz (UCSC) GRCh37/hg19 reference genome using Burrows-Wheeler Aligner (BWA) software (version 0.7.17). The Genome Analysis ToolKit (GATK) software (version 4.2.1.0) was used for single nucleotide polymorphisms/variants (SNPs/SNVs) and short insertions/deletions (INDELs) (<50 bp) calling. Samtools (version 1.22.1) and Picard software (version 2.22.1) packages were used to generate high-quality binary alignment map (BAM) data by removing duplicate reads. CNV detection from WES data was performed using the Multi-Scale. Reference (MSR) algorithm built into NxClinical version 6.1 software (Bionano, San Diego, CA). Variants were annotated for analysis using the single nucleotide polymorphism database (dbSNP, version 5.3), gnomAD exomes database (version 4.1.0) and Chigene in-house minor allele frequency (MAF) database. Tools of pathogenicity prediction like REVELAL and AlphaMissense were used for predicting possible impact of variants. As a prioritized pathogenicity annotation to the American College of Medical Genetics and Genomics (ACMG) guidelines, Online Mendelian Inheritance in Man (OMIM), Human Gene Mutation Database (HGMD) and ClinVar databases were used as conferences of pathogenicity of every variant. Variants classification The result of filter process of WES: thirteen variants in 12 genes were identified through thorough analysis of all genes for putative dominant disease-causing variants. Only one variants in one genes were associated with this patient’s phenotypes of hydrops fetalis (HP:0001789). The excluded 11 genes were as follows: NFKB2, APOA4, ARHGEF10, CHD6, DVL3, GALK1, LILRB2, MBD4, ORAI1, OSMR, PDX1. All of these rare phenotype-related variants were classified by following the guidelines of ACMG for interpreting sequence variants. Classification considered the position of the variant in the human genome, MAF, the pathogenicity prediction of variants, disease mechanism, clinical phenotypes, literature evidence, evolutionary conservation. Variants verification Fetal and parental gDNA samples was used for the verification of this variant. All reactions were carried out in a total volume of 20 μL using the Taq DNA polymerase. After confirmation of the size of the amplicons, the PCR products were purified by standard protocol. The reaction system was: 2 μL DNA (10 ng/μL), 1 μL forward primer, 1 μL reverse primer, 10 μL PCR Master Mix, 6 μL free RNA H2O. The following protocol of PCR: initial denaturation at 95 °C for 3 min, followed by 30 cycles at 95 °C for 30 s, 60 °C for 30 s, and 72 °C for 30 s, with a final elongation at 72 °C for 10 min. The PCR products were electrophoresed on a 2.0% agarose gel and were sequenced. The primers were as follows: 5′-AGT​GGC​AAG​TGT​GTC​AAA​GGT​T -3′ and 5′-GCT​CAC​CTA​AGT​ACA​ATC​AGA​AAA​GT-3′. Sanger sequenced using the BigDye Terminator v3.1 Cycle Sequencing Kit (ABI 3730 Applied Biosystem, United States of America) for the verification of candidate variants. The identification of this variant was performed using Chromas software (version 2.2.6, Technelysium, Australia). Construction of the RPL15 variant in vitro and transfection The coding DNA sequence RPL15 gene is 615 base pairs. Mutant pcDNA3.1 (+)-FLAG-RPL15-mut, wild-type pcDNA3.1 (+)-FLAG-RPL15-wt and negative control empty mammalian expression vectors were constructed and purchased from Wuhan Biorun Biosciences Co., Ltd. Human embryonic kidney (HEK)-293 T cells were transfected with the above three expression vectors in separate tubes (one for the mutant expression vector, one for the wild-type expression vector, and one for the empty control vector). The constructed expression vectors were verified using Sanger sequencing. Then, 6 hours after the transfection, we gently removed the lipofectamine-containing medium, replaced the medium with Dulbecco’s modified Eagle medium (DMEM) containing 5% fetal bovine serum (FBS), and incubated the slide at 37 °C in a 5% CO2 incubator until day 2. On day 3, the samples were collected and used in a reverse transcription-polymerase chain reaction (RT-PCR) to quantify the RPL15 mRNA expression and the Western blot (WB) assay to quantify the RPL15 protein expression. Each cell line underwent three independent replicates of the RT-PCR and WB assays. The RT-PCR and Western blotting experiments were conducted in accordance with the manufacturer’s instructions. Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) Wild-type (RPL15-wt), mutant (RPL15-mut) and empty vector negative control expression vectors were respectively transfected into HEK293 T cells. All samples were collected at 24 h, 48 h, and 72 h post-transfection for subsequent analysis. The transfected cells were collected by centrifugation, followed by total RNA extraction using the Trizol method. Total RNA concentration and quality were checked using a NanoDrop 2000 spectrophotometer (Thermo Fisher Scientific, United States of America). Complementary DNA (cDNA) was synthesized using NovoScript® Plus All-in-one 1st Strand cDNA Synthesis SuperMix (Novoprotein, China) following the manufacturer’s instructions. The cDNA concentration was about 1,200 ng/μL. The total reaction system was 20 μL, with 500 ng of total RNA used as a template. Quantitative PCR was performed using the Maxima SYBR Green/ROX qPCR Master Mix (2×) (Thermo Fisher Scientific, United States of America). Relative RPL15 mRNA expression levels were determined using 2−ΔΔCt method, and the ACTB gene was used as the reference gene. The experimental values were normalized to the empty-24 h condition, designated as the internal control. The qRT-PCR reaction was performed in triplicate, and mean values and standard deviations were calculated from the obtained data. The qPCR primer sequences for RPL15 were 5′-TTT​CTT​CTG​AGG​GTC​CGC​TG-3′ and 5′-ACG​TAA​CCT​TGC​TTG​GCC​TT-3’. The qPCR primer sequences for ACTB were 5′-CAT​GTA​CGT​TGC​TAT​CCA​GGC3′ and 5′-CTC​CTT​AAT​GTC​ACG​CAC​GAT-3’. Western blot (WB) Wild-type (RPL15-wt), mutant (RPL15-mut) and negative control empty expression vectors were separately transfected into HEK293 T cells. All samples were collected at 24 h, 48 h, and 72 h post-transfection for subsequent analysis. Western blot analysis was subsequently performed using standard protocol. Equal amounts of protein were resolved by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and subsequently transferred onto polyvinylidene fluoride (PVDF) membranes. Membranes were blocked with 5% non-fat milk in a tris buffered saline with tween-20 (TBST) solution for 2 h at room temperature. Anti-Flag (MBL, Japan, dilution ratio is 1:1,000) and anti-β-Actin dilutions were added respectively and incubated at 4 °C overnight. Horseradish peroxidase (HRP)-labeled secondary antibodies were added and incubated at room temperature for 1 h β-Actin served as the loading control and internal reference protein. The loading amount of WB protein was 10 μg/well. Blot bands were quantified by densitometry using ImageJ software (ImageJ2). Protein levels were normalized to β-Actin. The relative RPL15 protein expression levels are quantified by the fold change (FC) in the ratio of the grayscale between the RPL15 protein band and the internal reference protein band. Transcription inhibition Actinomycin D is an inhibitor of mRNA and protein synthesis. Actinomycin D can directly bind to the guanine groups of single-stranded or double-stranded DNA in the transcriptional initiation complex, inhibit the activity of DNA-dependent RNA polymerase, and interfere with the transcription process of DNA, thereby inhibiting mRNA synthesis. Actinomycin D (10 μg/mL) was used to analysis the degradation of RPL15 mRNA. Wild-type (RPL15-wt) and mutant (RPL15-mut) expression vectors were respectively transfected into HEK293 T cells for 48 h, then treated with actinomycin D for 0, 4, 8, and 12 h. RT-qPCR was used to detect the expression of wild-type and mutant mRNA. Experimental data were normalized to the respective 0-h baseline measurements. Statistical analysis Multiple comparisons across these experimental groups were performed using the Holm-Šídák multiple comparisons test in Prism software (GraphPad Prism 10.6.0). P < 0.05 was considered statistically significant. Literature review We systematically searched the PubMed database for relevant published studies on the research topic using “RPL15 gene” as keywords. The search time was from the establishment of the databases to 28 February 2026. We reviewed RPL15-related cases with availability of clinical data including relevant genetic testing results, prenatal/postnatal manifestations. Results Clinical features A 28-year-old woman (gravida 0, para 0) at 31+2 weeks gestation presented to our hospital reporting decreased fetal movements that had persisted for 1 day. On the morning prior to admission, the pregnant woman reported a noticeable decrease in fetal movements. Examination performed on the same day showed that the fetal heart rate was within the normal range. The following day, color Doppler ultrasound (Mindray® Resonar9t with SC6-1U ultrasound transducer, Shenzhen, China) revealed no detectable fetal heart rate or fetal movements, suggesting intrauterine fetal death. The fetal Doppler ultrasound scan revealed the following fetal findings: fetal position: left occipital anterior (LOA); biparietal diameter: 74 mm (−1.5 SD); head circumference: 265 mm (−2.6 SD); adominal circumference: 339 mm (4.9 SD); femur length: 50 mm (−2.9 SD). Ultrasound scan () revealed fetal scalp edema with a maximum thickness of approximately 5.7 mm, right thoracic pleural effusion measuring approximately 9.3 mm in width, and fetal abdominal ascites measuring approximately 15.2 mm in width. The woman delivered the stillborn infant on the second day after admission. The birth weight was 2020g. The infant presented with generalized marked edema. The external genitalia were ambiguous (). This primigravida with an unremarkable medical history denied consanguinity and exposure to teratogenic or hazardous substances. Routine first-trimester serum screening and non-invasive prenatal testing (NIPT) performed at our institution yielded normal results. No pathogenic microorganism nucleic acids were detected in the peripheral blood and amniotic fluid samples of the pregnant woman through microbiological testing (including nucleic acid amplification tests for bacteria and viruses); biochemical indicators of liver and kidney function, as well as 12-lead electrocardiogram results, were all within age- and gestation-specific reference ranges. The woman declined the pathological examination but agreed to genetic testing only, thus preventing the acquisition of other characteristic clinical information. A1: scalp edema with a maximum thickness of approximately 5.7 mm (indicated by the arrow). A2: pleural effusion of approximately 9.3 mm wide in the right thoracic cavity (showed by the arrow). A3: ascites of approximately 15.2 mm wide in the fetal abdominal cavity (showed by the arrow). Genetic analysis and confirmation Copy-number variants (CNVs) analysis of WES did not show abnormity. WES did not revealed pathogenic or likely pathogenic variants in genes associated with inherited metabolic disorders. WES identified a novel heterozygous frameshift RPL15 gene variant (NM_002948.5) c.227del (p.Pro76Leufs*17), it was a de novo variant. This variant was further verified by Sanger sequencing (). The allele frequency of this heterozygous variant has not been registered in population databases (1,000 Genomes Project, gnomAD, and dbSNP) or reported in disease databases (HGMD, OMIM) (PM2_Supporting). This fetus was the only de novo occurrence of this variant (PS2_Supporting). The probability of being loss-of-function (LoF) intolerant (pLI) value of RPL15 gene in the gnomAD (v4.1.0) was 1.000, which indicated that RPL15 gene was extremely intolerant to LoF variants (pLI>0.9). This variant in RPL15 gene was not predicted to cause nonsense-mediated mRNA decay (NMD), the truncated region was critical to protein function (PVS1_Strong) (see ). As per the interpretation guidelines by ACMG (), this novel variant was classified as “likely pathogenic”. We have submitted this variant to a public database [Leiden Open Variation Database (LOVD)], and the accession number can be found at the following URL: https://databases.lovd.nl/shared/individuals/00468037. Functional analysis of this frameshift variant Sanger sequencing was performed to validate the full-length cDNA (NM_002948.5) of the RPL15 gene in both wild-type and mutant cell lines. Sanger sequencing verified the successful construction of the mutant expression plasmid harboring the c.227del variant, prior to transfection of the overexpression plasmid (). To evaluate the effect of this frameshift RPL15 variant, our functional studies revealed that this RPL15 variant, c.227del, markedly decreased mRNA expression of RPL15 gene (), leading to a lack of normal RPL15 protein () compared to the RPL15-wt cell lines. As actinomycin D can bind to DNA to form a complex, hinder the function of RNA polymerase, and specifically inhibit mRNA synthesis, after actinomycin D treatment, RT-qPCR results indicated that mRNA transcription was inhibited in both the RPL15-wt and RPL15-mut groups; however, the RPL15-mut group exhibited a significantly accelerated mRNA decay rate and lower steady-state mRNA levels relative to the RPL15-wt group (). This study hypothesized that this frameshift RPL15 variant predicted to escape NMD may be subject to some certain mechanisms for degrading mutant mRNA. Based on these cases with frameshift/nonsense variants (eight cases) and deletions/intragenic deletions in the RPL15 gene (three cases), we postulated that clinical phenotypes may be caused by LoF effects of RPL15 variants and a molecular mechanism of DBA may be associated with haploinsufficiency of RPL15 gene. The pLI value of RPL15 gene in the gnomAD (v4.1.0) was 1.000, which indicated that RPL15 gene was extremely intolerant to LoF variants (pLI>0.9). But the gene dosage sensitivity curation from ClinGen showed the little evidence for haploinsufficiency of RPL15 gene (last evaluated time: 07/16/2014). This novel c.227del (p.Pro76Leufs*17) variant was a presumed LoF variant, which represented a putative mechanism underlying gene haploinsufficiency. Theoretically, this variant introduced a premature termination codon (PTC), resulting in premature translational termination and the production of a truncated protein comprising 91 amino acids (approximately 44.6% of the wild-type protein length). The 50bp rule for predicted NMD escape was first described by Nagy and Maquat (). Validation of the exon junction complex (EJC)-dependent model and start-proximal NMD insensitivity were described by , (). If a PTC occurs close to the start or end of the transcript (NMD escape region defined as within the first 100bp of coding sequence, the last 50-55bp of the penultimate exon and the entire last exon coding sequence), then the corresponding transcript is predicted to escape NMD and thus avoids mRNA degradation. In accordance with this rule, this variant (c.227del) was located within the last 50-55bp of the penultimate exon coding sequence and was therefore predicted to escape NMD (). 3A: The experimental values were normalized to the empty-24 h condition, designated as the internal control. The results of RT-PCR analysis showed that the mRNA expression of mutant RPL15 cell lines was significantly decreased. Compared with RPL15-wt cell lines harvested at 24, 48, and 72 h post-transfection, each cell line was subjected to three independent biological replicates of the RT-PCR assay. The difference between RPL15-wt and RPL15-mut was assessed using the Holm-Šídák test, with ****P < 0.0001. 3B: The relative RPL15 protein expression was quantified by the fold change (FC). WB analysis indicated that the relative expression level of RPL15 protein in the RPL15-mut cell lines was significantly lower than that in the RPL15-wt cell lines harvested at 48 and 72 h post-transfection. From 24 to 48 h, FC of RPL15-mut cell line showed a slow downward trend (increasing from 0.87 to 0.70), while from 48 to 72 h, it exhibited a more significant downward trend (decreasing from 0.70 to 0.45). Each cell line underwent three independent biological replicates of WB analysis. The difference between RPL15-wt and RPL15-mut was evaluated by Holm-Šídák test. **P < 0.01, ****P < 0.0001, ns: not significant. Note: this is FLAG (exogenous protein only) detection. Discussion The RPL15 gene (ribosomal protein L15, OMIM*604174) is located on chromosome 3p24.2 (chromosome 3: 23,917,132–23,920,989 forward strand, GRCh38. p14). The transcript of RPL15 gene (NM_002948.5) has four exons (3 coding exons) with the transcript length of 2,155 base pairs (Figure 5A). Its translation product consists of 204 amino acid residues (UniProt database accession P61313). The ribosomal protein L15 is a component of the large 60 S ribosomal subunit (). The RPL15 protein is localized in the cytoplasm and plays structural and functional roles in ribosome assembly and protein synthesis. Functional role in the biogenesis of ribosomes and the process of protein synthesis. During the ribosome assembly stage, RPL15 protein works in concert with other ribosomal proteins and rRNA to promote the maturation of the 60 S subunit (). Overexpression of RPL15 protein has been observed in esophageal cancer (), gastric cancer tissues (), breast cancer () and intrahepatic cholangiocarcinoma (). Deletion of this gene has been observed in Diamond-Blackfan anemia syndrome patients. DBA syndrome is a bone marrow failure syndrome (BMFS) characterized primarily by erythroid hypoplasia, other non-hematologic manifestations, and an increased risk of cancer (). We found that the gene-disease validity curation from Gene Curation Coalition (GenCC) showed the “strong” gene-disease validity of RPL15 gene (last evaluated time: 04/01/2021). To date, the gene-disease validity of the RPL15 gene has not been curated in the Clinical Genome Resource (ClinGen) database. The RPL15-related autosomal dominant Diamond-Blackfan anemia 12 (DBA12, OMIM#615550) has been reported in eight studies, encompassing a total of 14 patients aged 0–22 years. We retrospectively reviewed a total of 11 patients with heterozygous missense/frameshift/nonsense RPL15 variants (SNVs/indels) and a total of three patients with deletions or intragenic deletions affecting the RPL15 gene. Although all these patients were diagnosed with DBA, three of whom lacked detailed clinical documentation. The most prevalent shared clinical features observed among the 11 patients included congenital anemia presenting within the first 6 months of life (100%, 11/11), and three patients had undergone prenatal intrauterine transfusion. Other non-hematologic manifestations included developmental delay (DD) (27%, 3/11), intellectual disability (ID) (18%, 2/11), cerebral palsy (18%, 2/11), abnormalities of the cardiovascular system (36%, 4/11), dysmorphic facial features (36%, 4/11), renal malformations (18%, 2/11), abnormalities of the male genitalia (18%, 2/11). No significant differences in clinical phenotypes were observed between individuals harboring RPL15 gene SNVs/indels and those with RPL15 gene deletions or intragenic deletions. The penetrance of SNVs/indels in the RPL15 gene appeared to be incomplete. , () reported two variants (c.242dupA and c.29 T>C), each inherited from phenotypically unaffected parents; all affected offspring carrying the variants were clinically diagnosed with DBA. , () reported one patient with the c.313C>T (p.Arg105*) variant inherited from the healthy 24-year-old mother with short stature (152 cm). Among a total of 10 cases with reported prenatal examination records (including our case), we found the pregnancies of 9/10 cases were eventful. Among the nine eventful pregnancies, hydrops fetalis was observed in five cases (56%), fetal growth restriction in five cases (56%), fetal cardiovascular abnormalities in three cases (43%), and decreased fetal movements in three cases (43%). Other abnormal features were extremity abnormalities and placenta previa. All these patients reported in the literature survived, among which three patients had received intrauterine transfusions. In our case, the fetus developed hydrops fetalis and subsequently died in the perinatal period at 31 weeks’ gestation, presenting with ambiguous external genitalia and a normal chromosome karyotype of 46,XY. The lethality associated with the RPL15 variants was recapitulated in the mutant zebrafish model. There is currently no published evidence linking the atypical phenotype of ambiguous genitalia to pathogenic variants in RPL15 gene. Given that this finding has been observed in only two patients to date, a causal relationship cannot be established, and the association may reflect coincidental co-occurrence, differences in genetic background, or the influence of unidentified modifying factors. We have conducted in vitro functional studies on this variant. In fact, we found that the regions predicted to escape NMD were not always consistent with the actual experimental results. RT-PCR showed that the mRNA expression of mutant RPL15 cell lines was significantly decreased compared with that in the RPL15-wt cell lines at 24, 48, and 72 h post-transfection (). RPL15-mut cell lines produced truncated protein (). Western blot analysis revealed that the relative expression level of RPL15 protein in RPL15-mut cell lines was significantly reduced compared with that in RPL15-WT cell lines at 48 and 72 h post-transfection (). Following actinomycin D treatment, the RPL15-mut group exhibited a significantly accelerated mRNA decay rate and lower steady-state mRNA levels relative to the RPL15-wt group. To sum up, we speculated that this mutant mRNA (predicted to escape NMD) remained subject to degradation, thereby reducing mutant protein synthesis and inducing haploinsufficiency of the RPL15 gene, which underlies the pathogenesis of Diamond-Blackfan anemia. Furthermore, two nonsense variants (c.313C>T, c.295C>T) located downstream of this novel stop codon and one nonsense variant (c.85C>T) within the first 100bp of coding sequence (also predicted to escape NMD) have been reported in three patients with DBA (). The truncated region resulting from these variants overlaps with the evolutionarily conserved, functionally critical protein domain “Ribosomal_eL15” (domain source: Pfam; accession: PF00827). During the earliest assembly stages of the large 60 S ribosomal subunit, eL15—alongside its neighboring ribosomal proteins eL8 and eL36—cooperatively shaped the 25S/5.8 S rRNA domain I. Deletion of RPL15 affects the assembly and stability of the ribosome and efficient protein production. In vivo depletion of yeast eL15 resulted in the deficit of 60 S subunits and the appearance of half-mer polysomes (). , () identified a variant c.242dupA (p.Tyr81*) in three unrelated patients diagnosed with DBA. Subsequently, several in vitro functional assays were performed. They found that the variant c.242dupA (p.Tyr81*) impaired pre-rRNA processing, reduced 60 S ribosomal subunit formation, decreased de novo protein synthesis, decreased the number of erythroid colonies, and delayed in differentiation, in addition to inducing increased apoptosis, TP53 stabilization, and p21 overexpression in RPL15-mutant hematopoiesis. Collectively, they were the first to propose the hypothesis that RPL15 variants could cause haploinsufficiency and lead to a reduction in ribosomal protein levels. In vivo knockdown the RPL15 in human A549 cells decreased free 60 S ribosomal subunit while concomitantly increasing the abundance of free 40 S subunit (). Downregulation expression of rpl15 in zebrafish by microinjection of rpl15 morphilino antisense oligo () and knocking out zebrafish rpl15 gene by CRISPR/Cas9 editing technique () showed that downregulation of rpl15 inhibited the early hematopoietic development of zebrafish and the mutant rpl15 produced abnormal phenotypes (developmental delay, smaller head, shorter body length, curved tail, pericardial edema and reduced hemoglobin synthesis in erythrocytes) similar to Diamond-Blackfan anemia, approximately 95% of the mutant zebrafish died within 7–10 days after fertilization. Integrating evidence from literature review, clinical case/variants characterization, in vitro cellular functional assays, and data from RPL15 gene knockout animal models, we supports a preliminary and prudent conclusion that RPL15 gene variants may exhibit dosage-sensitive pathogenicity. In summary, we report herein the fetal death may be associated with a novel RPL15 gene variant. This study is based on a single-family cohort; therefore, additional cases sharing analogous clinical and genetic profiles are thus required to rigorously validate the causal relationship between RPL15 variants and perinatal death. Clinicians should prioritize close follow-up and multidisciplinary management for patients or fetuses carrying RPL15 variants. The penetrance of LoF variants in the RPL15 gene is high, but appears to be incomplete. Therefore, during prenatal diagnosis, genetic counseling for fetuses carrying pathogenic RPL15 variants but without clinical phenotypes should be conducted with caution. Current literature and our in vivo functional analysis collectively indicate that RPL15 haploinsufficiency underlies the pathogenesis of RPL15-associated DBA ().